Graves Disease

2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Immunovant
ImmunovantDURHAM, NC
1 program
1
IMVT-1401Phase 21 trial
Active Trials
NCT05907668CompletedEst. Jul 2025
Biohaven
BiohavenNEW HAVEN, CT
1 program
1
BHV-1300Phase 11 trial
Active Trials
NCT06980649RecruitingEst. Mar 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
ImmunovantIMVT-1401
BiohavenBHV-1300

Clinical Trials (2)

NCT05907668ImmunovantIMVT-1401

A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Start: May 2023Est. completion: Jul 2025
Phase 2Completed
NCT06980649BiohavenBHV-1300

Study of BHV-1300 in Graves' Disease

Start: Aug 2025Est. completion: Mar 2026
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
2 companies competing in this space